Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Urology

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.UROLOGY.2007.01.075PMID 17482937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006cited by this paper
• Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

  2005cited by this paper
• Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

  2005cited by this paper
• Improved detection of prostate cancer using classification and regression tree analysis.

  2005cited by this paper
• The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA

  2004cited by this paper
• Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

  2004cited by this paper
• Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.

  2003cited by this paper
• Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era.

  2003cited by this paper
• Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL

  2003cited by this paper
• PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

  2002cited by this paper
• Novel artificial neural network for early detection of prostate cancer.

  2002cited by this paper
• Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

  1999cited by this paper
• Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer

  1998cited by this paper
• Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients.

  1997cited by this paper
• Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.

  1993cited by this paper
• Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

  1992cited by this paper
• Hudson et al.

  1977cited by this paper

• Prostate Specific Antigen Dynamics and Features in Prostate Cancer

  2021cites this paper
• [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer].

  2015cites this paper
• Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.

  2011cites this paper
• Parâmetros cinéticos do PSA em pacientes submetidos à biópsia de próstata

  2010cites this paper
• PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer

  2010cites this paper
• [The screening of prostate cancer in 2009: overview of the oncology committee of the French Urological Association].

  2010cites this paper
• Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.

  2009cites this paper
• PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.

  2009cites this paper
• Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.

  2009cites this paper
• DEVELOPMENT OF NOVEL ASSAYS FOR MEASURING DIFFERENT MOLECULAR FORMS OF PROSTATE SPECIFIC ANTIGEN

  2009cites this paper
• Le dépistage du cancer de la prostate en 2009 : mise au point du comité de cancérologie de l’Association française d’urologie The screening of prostate cancer in 2009: Overview of the oncology committee of the French Urological Association

  2009cites this paper
• Lebensqualität nach radikaler Prostatovesikulektomie in Abhängigkeit vom intraoperativen Erhalt des Gefäß-Nerven-Bündels

  2009cites this paper
• Development of Novel Assays for Measuring Different Molecular Forms of Prostate Specific Antigen

  2009cites this paper
• Celebrating 25 years of research and training in cancer in Africa : a historical perspective of the African Organization for Research and Training in Cancer ( AORTIC )

  2008cites this paper
• A study of PSA values in an unselected sample of Senegalese men.

  2008cites this paper
• Current applications for prostate-specific antigen doubling time.

  2008cites this paper
• Optimal measure of PSA kinetics to identify prostate cancer.

  2008cites this paper
• Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.

  2008cites this paper
• The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

  2008cites this paper
• Ambulatory and Office Urology ptimal Measure of PSA Kinetics to Identify rostate Cancer

  2008cites this paper
• Early Prostate Cancer, On prognostic markers and predictors of treatment outcome after radical prostatectomy.

  2007cites this paper